Prostate cancer DNA vaccine - Cellectis/Karolinska Institute

Drug Profile

Prostate cancer DNA vaccine - Cellectis/Karolinska Institute

Alternative Names: pVAXrcPSAv53l

Latest Information Update: 22 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cyto Pulse Sciences; Karolinska Institute
  • Developer Cellectis; Karolinska Institute
  • Class Cancer vaccines; DNA vaccines; Gene therapies
  • Mechanism of Action Gene transference; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Prostate cancer

Most Recent Events

  • 31 Dec 2008 Phase-I/II clinical trials in Prostate cancer in Sweden (Intradermal)
  • 11 Oct 2008 The Swedish Medical Products Agency approves clinical trial application for DNA vaccine in Prostate cancer
  • 17 May 2007 Preclinical data added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top